{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:02Z","timestamp":1761515882146,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.4158\/ep11287.cr","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T21:14:03Z","timestamp":1332882843000},"page":"e32-e36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reversible Mitral and Aortic Regurgitation Due to Pioglitazone"],"prefix":"10.1016","volume":"18","author":[{"given":"Sunil K.","family":"Kota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhas R.","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siva K.","family":"Kota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruti","family":"Jammula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirtikumar D.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP11287.CR_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","article-title":"Nonhypoglycemic effects of thiazolidinediones [published correction appears in Ann Intern Med. 2001135:307]","volume":"134","author":"Parulkar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.4158\/EP11287.CR_bb0015","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/dc07-0141","article-title":"Thiazolidinediones and heart failure: a teleo-analysis","volume":"30","author":"Singh","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11287.CR_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.290.1.81","article-title":"Metformin and thiazolidinedione use in Medicare patients with heart failure","volume":"290","author":"Masoudi","year":"2003","journal-title":"JAMA"},{"key":"10.4158\/EP11287.CR_bb0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"10.4158\/EP11287.CR_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/030006059902700201","article-title":"Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors","volume":"27","author":"Bando","year":"1999","journal-title":"J Int Med Res"},{"key":"10.4158\/EP11287.CR_bb0035","first-page":"E989","article-title":"Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats","volume":"272","author":"Yoshimoto","year":"1997","journal-title":"Am J Physiol"},{"key":"10.4158\/EP11287.CR_bb0040","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0022-3565(24)35008-6","article-title":"Troglitazone inhibits bicarbonate secretion in rat and human duodenum","volume":"290","author":"Hosokawa","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.4158\/EP11287.CR_bb0045","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2337\/diabetes.47.5.810","article-title":"Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro","volume":"47","author":"Walker","year":"1998","journal-title":"Diabetes"},{"key":"10.4158\/EP11287.CR_bb0050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2337\/diacare.24.5.953","article-title":"The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients","volume":"24","author":"Baba","year":"2001","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11287.CR_bb0055","first-page":"A416","article-title":"Tolerability profile of pioglitazone in combination with a sulfonylurea or metformin in controlled clinical trials","volume":"50","author":"Belcher","year":"2001","journal-title":"Diabetes"},{"key":"10.4158\/EP11287.CR_bb0060","first-page":"A110","article-title":"Combination therapy with pioglitazone and insulin in patients with type 2 diabetes","volume":"48","author":"Rubin","year":"1999","journal-title":"Diabetes"},{"key":"10.4158\/EP11287.CR_bb0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.107.749440","article-title":"Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation","volume":"118","author":"Chaput","year":"2008","journal-title":"Circulation"},{"key":"10.4158\/EP11287.CR_bb0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1475-2840-7-12","article-title":"Treatment with pioglitazone induced significant, reversible mitral regurgitation","volume":"7","author":"Dorkhan","year":"2008","journal-title":"Cardiovasc Diabetol"},{"key":"10.4158\/EP11287.CR_bb0075","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jacc.2005.09.032","article-title":"Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography","volume":"47","author":"Oh","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP11287.CR_bb0080","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1161\/CIRCULATIONAHA.105.579268","article-title":"A clinician's guide to tissue Doppler imaging","volume":"113","author":"Ho","year":"2006","journal-title":"Circulation"},{"key":"10.4158\/EP11287.CR_bb0085","unstructured":"Actos (pioglitazone hydrochloride) [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc; 2000."},{"key":"10.4158\/EP11287.CR_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.48.3.609","article-title":"Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts","volume":"48","author":"Shimoyama","year":"1999","journal-title":"Diabetes"},{"key":"10.4158\/EP11287.CR_bb0095","first-page":"A124","article-title":"Long-term echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone","volume":"49","author":"Schneider","year":"2000","journal-title":"Diabetes"},{"key":"10.4158\/EP11287.CR_bb0100","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc10-0452","article-title":"Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study","volume":"33","author":"Bailey","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP11287.CR_bb0105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11010-008-9848-8","article-title":"Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin\/NFAT signaling pathway","volume":"317","author":"Bao","year":"2008","journal-title":"Mol Cell Biochem"},{"key":"10.4158\/EP11287.CR_bb0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0092-8674(00)81573-1","article-title":"A calcineurin-dependent transcriptional pathway for cardiac hypertrophy","volume":"93","author":"Molkentin","year":"1998","journal-title":"Cell"},{"key":"10.4158\/EP11287.CR_bb0115","doi-asserted-by":"crossref","first-page":"22295","DOI":"10.1074\/jbc.M801296200","article-title":"NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure","volume":"283","author":"Bourajjaj","year":"2008","journal-title":"J Biol Chem"},{"key":"10.4158\/EP11287.CR_bb0120","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1161\/hc4601.099403","article-title":"In vivo myocardial protection from ischemia\/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone","volume":"104","author":"Yue","year":"2001","journal-title":"Circulation"},{"key":"10.4158\/EP11287.CR_bb0125","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1161\/01.CIR.0000039346.31538.2C","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction","volume":"106","author":"Shiomi","year":"2002","journal-title":"Circulation"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041506X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041506X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/T7813276163R718H.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:54:13Z","timestamp":1761515653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2041506X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1530891X2041506X"],"URL":"https:\/\/doi.org\/10.4158\/ep11287.cr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible Mitral and Aortic Regurgitation Due to Pioglitazone","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP11287.CR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}